Sunday, February 6, 2011

Aurobindo Pharma Limited = RESULTS = Q 3 FY 2011 = QTR ENDING DECEMBER 2010 = CONSOLIDATED NPT UP BY 9.8%




Aurobindo Pharma Limited
NSE Symbol AUROPHARMA

Aurobindo Pharma has declared consolidated results for third quarter ending December, 201o.

NET SALES  is Rs.1192 cr – up by 7.15% from Q2 FY 2011 and up by 30.26% from Q3 FY 2010.

Total Expenditure is Rs.912 cr – up by 10.82% fromQ2 FY 2011 and up by 29.05% from Q3 FY 2010.

Profit from Operations is Rs.280 Cr – down by 3.28% from Q2 FY 2011 and UP by 34.33% from Q3 FY 2010.

Consolidated Net Profit is Rs.189 cr – down by 4.89% fromQ2 FY 2011 and up by 9.8% from Q3 FY 2010.

Basic EPS is Rs.32.4 compared to Rs.34.37 in Q2 FY 2011 and Rs.31.9 in Q3 FY 2010.

RESULTS TABLE :

Q3 FY 11
Net Sales
119220
111262
91524
DIF %1
1192
7.15
30.26
Incre./Decre. in SIT / WIP
-10687
-3215
-9770
Raw Materials
63609
55364
47157
Traded goods
4161
3327
3528
Employees Cost
10804
10737
9013
Depreciation
4335
4071
4037
Other Expenditure
18977
12008
16710
Total Expenditure
91199
82292
70670
DIF %2
912
10.82
29.05
Profit from Operations
28021
28970
20860
DIF %3
280
-3.28
34.33
Other Income
588
1058
370
Interest
1146
1927
1270
Profit before tax
27463
28101
22440
Tax Expense
7825
8297
5490
Net Profit
18872
19804
17180
Consolidated Net Profit
18863
19832
17177
DIF %4
189
-4.89
9.8
Face Value (in Rs.)
5
5
5
Paid-up Equity
2911.2
2911
2700
Basic EPS
32.4
34.37
31.9
Diluted EPS
29.18
30.92
26.57

"We continue to see a strong momentum in our formulations business with the scaling up of operations of the large formulations units in Jedcherla SEZ near Hyderabad, India and New Jersey, USA," the company  said in a statement.

The Hyderabad-based company filed 15 abbreviated new drug applications (ANDA) during the third quarter taking the cumulative filings to 200.

Aurobindo Pharma, during the quarter, has also filed 54 dossier filings in Europe, taking the cumulative filings to 906.

Last month, the company had announced to divest nearly 80 per cent of its stake in its loss-making Chinese subsidiary Aurobindo (Datong) Bio Pharma Co Ltd (ADBPL) to China National Pharmaceutical Group Corporation (Sinopharm).

 *  *  *   E  N   D   *   *  *

No comments:

Post a Comment